Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to confirm whether SmartVest reimbursement rates lifted Electromed’s margins or to track executive stock sales hidden in Form 4 PDFs can feel like wading through dense technical language and FDA jargon. Electromed’s SEC documents pack clinical trial data, quality-system risks, and payer disclosures into hundreds of pages—precisely the information analysts need yet struggle to find quickly.
Stock Titan’s AI-powered engine decodes every filing the moment it hits EDGAR. Whether you search “Electromed quarterly earnings report 10-Q filing” for unit-sales trends, or “Electromed insider trading Form 4 transactions” to gauge management sentiment, our platform delivers plain-English highlights, context, and red-flag alerts. Real-time feeds push “Electromed Form 4 insider transactions real-time” notices to your dashboard, while concise summaries turn a 300-page annual report into a two-minute brief.
You’ll find every document type in one place:
- 10-K: see SmartVest revenue segments and reimbursement risk factors—“Electromed annual report 10-K simplified”.
- 10-Q: quarter-over-quarter supply-chain costs with “Electromed earnings report filing analysis”.
- 8-K: “Electromed 8-K material events explained” when new clinical data or FDA correspondence surfaces.
- DEF 14A proxy: drill into “Electromed proxy statement executive compensation”.
Stop scrolling line-by-line through EDGAR. From “understanding Electromed SEC documents with AI” to pinpointing “Electromed executive stock transactions Form 4”, our coverage transforms complex disclosures into actionable clarity so you can focus on investment decisions, not document hunting.
The Vanguard Group filed Amendment 13 to its Schedule 13G disclosing a 7.01 % passive stake in Eagle Bancorp Inc. (EGBN) as of 30 Jun 2025. Vanguard reports beneficial ownership of 2,130,538 common shares (CUSIP 268948106).
Voting authority remains minimal: 0 shares sole vote and 47,739 shares shared vote. Dispositive power is larger, with 2,051,347 shares sole dispositive and 79,191 shares shared dispositive. The filing is made under Rule 13d-1(b) as Vanguard is an investment adviser (IA), indicating the position is held in the ordinary course of business rather than to influence control.
No indication of transactions, purchase dates, or prior ownership levels is provided, so direction of change versus previous filings cannot be determined. Certification is signed by Ashley Grim, Head of Global Fund Administration, on 29 Jul 2025.
FAQ
What is the current stock price of Electromed (ELMD)?
What is the market cap of Electromed (ELMD)?
What is the primary focus of Electromed Inc?
How does the SmartVest system work?
What conditions can benefit from Electromed's technology?
Which regulatory standards does Electromed adhere to?
How does Electromed differentiate itself from competitors?
What is the significance of HFCWO in respiratory care?
Who are the primary customers of Electromed's products?
What role do clinical validations play in Electromed's offerings?
